Literature DB >> 12871759

Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice.

Kansu Büyükafşar1, Ismail Un.   

Abstract

Relaxant responses to two Rho-kinase inhibitors, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632) and fasudil, were compared in the corpus cavernosum obtained from diabetic and non-diabetic mice. Streptozotocin (100 mg kg(-1) day(-1), for 2 days) induced diabetes with a blood glucose level of 318+/-55.4 mg dl(-1); whereas it was 85.4+/-4.1 mg dl(-1) in control mice (P<0.05). Electrical field stimulation (40 V, 0.5 ms, 1, 2, 4, 8, 16 Hz for 15 s) and acetylcholine-induced relaxations were markedly attenuated in the corpus cavernosum from streptozotocin-diabetic mice whereas responses to Y-27632 (10(-9)-3 x 10(-5) M) and fasudil (10(-9)-3 x 10(-5) M) were not altered. EC(50) values for Y-27632 were 2.98+/-0.89 and 4.19+/-2.71 microM in the corpus cavernosum from control and diabetic mice, respectively (P>0.05). The values for fasudil were 7.42+/-4.91 and 3.53+/-1.41 microM in the corpus cavernosum from control and diabetic mice, respectively (P>0.05). These results may suggest that, in diabetes, the relaxant effects of the Rho-kinase inhibitors may not be changed and thus, they may have a beneficial therapeutic effect in diabetic erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871759     DOI: 10.1016/s0014-2999(03)01905-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.

Authors:  N Schlimmer; M Kratz; M Böhm; M Baumhäkel
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 2.  The future is today: emerging drugs for the treatment of erectile dysfunction.

Authors:  Maarten Albersen; Alan W Shindel; Kuwong B Mwamukonda; Tom F Lue
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 3.  RhoA/Rho-kinase and vascular diseases: what is the link?

Authors:  Kenia Pedrosa Nunes; Christine S Rigsby; R Clinton Webb
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

4.  Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter.

Authors:  Adnan Levent; Kansu Büyükafsar
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

5.  Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens.

Authors:  Kansu Büyükafşar; Adnan Levent; Mustafa Ark
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

6.  RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction.

Authors:  Trinity J Bivalacqua; Hunter C Champion; Mustafa F Usta; Selim Cellek; Kanchan Chitaley; R Clinton Webb; Ronald L Lewis; Thomas M Mills; Wayne J G Hellstrom; Philip J Kadowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

7.  Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation.

Authors:  Haroldo A Toque; Kenia P Nunes; Lin Yao; James K Liao; R Clinton Webb; Ruth B Caldwell; R William Caldwell
Journal:  J Sex Med       Date:  2013-04-08       Impact factor: 3.802

8.  Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa.

Authors:  Fabio Guagnini; Mara Ferazzini; Marco Grasso; Salvatore Blanco; Tiziano Croci
Journal:  J Transl Med       Date:  2012-03-23       Impact factor: 5.531

Review 9.  Advances in the treatment of erectile dysfunction: what's new and upcoming?

Authors:  Chintan K Patel; Nelson Bennett
Journal:  F1000Res       Date:  2016-03-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.